The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | PHE885, a T-Charge manufactured BCMA-directed CAR-T therapy in R/R myeloma
Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the benefits of PHE885, a BCMA CAR-T therapy manufactured in less than two days using the T-Charge platform, explaining that these CAR T-cells can get to the patient faster and expand in the patient, thereby preserving T-cell stemness. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
